Skip to main content
SpringerLink
Log in

Multiple Myeloma and Other Plasma Cell Neoplasms

  • Chapter
  • First Online:
Diagnosis of Blood and Bone Marrow Disorders

  • 2096 Accesses

Abstract

Plasma cell neoplasms (PCN) encompass a range of diseases ranging from indolent to aggressive. They include monoclonal gammopathy of undetermined significance (MGUS) (67%), multiple myeloma (14%), solitary plasmacytoma of the bone or extraosseous tissue (3%), primary amyloidosis (9%), immunoglobulin (Ig) chain deposition diseases (<1%), POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M component, and skin changes), and more recently recognized TEMPI syndrome (telangiectasias, elevated erythropoietin level and erythrocytosis, monoclonal gammopathy, perinephric fluid collections, and intrapulmonary shunting).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.

    Article  Google Scholar 

  2. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–9.

    Article  CAS  Google Scholar 

  3. Kyle RA, San-Miguel JF, Mateos MV, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am. 2014;28(5):775–90.

    Article  Google Scholar 

  4. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125(20):3069–75.

    Article  CAS  Google Scholar 

  5. Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013;31(34):4325–32.

    Article  Google Scholar 

  6. Bartl R, Frisch B. Clinical significance of bone marrow biopsy and plasma cell morphology in MM and MGUS. Pathol Biol. 1999;47(2):158–68.

    CAS  PubMed  Google Scholar 

  7. Paiva B, Merino J, San Miguel JF. Utility of flow cytometry studies in the management of patients with multiple myeloma. Curr Opin Oncol. 2016;28(6):511–7.

    Article  CAS  Google Scholar 

  8. Flores-Montero J, de Tute R, Paiva B, Perez JJ, Bottcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016;90(1):61–72.

    Article  CAS  Google Scholar 

  9. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335–48.

    Article  CAS  Google Scholar 

  10. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911–20.

    Article  CAS  Google Scholar 

  11. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067–76.

    Article  CAS  Google Scholar 

  12. Rosado FG, Oliveira JL, Sohani AR, Schroyens W, Sykes DB, Kenderian SS, et al. Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. Modern Pathol. 2015;28(3):367–72.

    Article  Google Scholar 

  13. Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol. 2016;91(9):947–56.

    Article  CAS  Google Scholar 

  14. Wolf BC, Kumar A, Vera JC, Neiman RS. Bone marrow morphology and immunology in systemic amyloidosis. Am J Clin Pathol. 1986;86(1):84–8.

    Article  CAS  Google Scholar 

  15. Hasserjian RP, Goodman HJ, Lachmann HJ, Muzikansky A, Hawkins PN. Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients. Histopathology. 2007;50(5):567–73.

    Article  CAS  Google Scholar 

  16. Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood. 2008;111(9):4700–5.

    Article  CAS  Google Scholar 

  17. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009;94(3):380–6.

    Article  CAS  Google Scholar 

  18. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–9.

    Article  CAS  Google Scholar 

  19. Sethi S, Fervenza FC, Rajkumar SV. Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. Curr Opin Nephrol Hypertens. 2016;25(2):127–37.

    Article  CAS  Google Scholar 

  20. Pozzi C, D'Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42(6):1154–63.

    Article  Google Scholar 

  21. Went P, Ascani S, Strom E, Brorson SH, Musso M, Zinzani PL, et al. Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. Lancet Oncol. 2004;5(6):381–3.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Pei Lin M.D.

Authors
  1. Pei Lin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pei Lin M.D. .

Editor information

Editors and Affiliations

  1. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Sa A. Wang

  2. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

    Robert P. Hasserjian

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lin, P. (2018). Multiple Myeloma and Other Plasma Cell Neoplasms. In: Wang, S., Hasserjian, R. (eds) Diagnosis of Blood and Bone Marrow Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-20279-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20279-2_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-20278-5

  • Online ISBN: 978-3-319-20279-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation